Fragrance Industry News: Strong Sales Trends In H1, Fefé For Dogs, And The Scent Every Pretzel Lover Kneads

 
• By Eileen Francis
  
Generate a summary of this article
Listen to this article
Beta

Inter Parfums, Inc.’s second quarter sales grew 11% on “robust” fragrance environment, strength of legacy brands and speedy ramp-up of new brands, CEO Jean Madar said. Meanwhile, Symrise’s Scent & Care division sales grew 12.1% in the 2024 first half, while Givaudan’s fragrance and beauty sales jumped 15.3%. More fragrance news.

• Source: Shutterstock

Inter Parfums, Inc. CEO Jean Madar cited the “robust” fragrance environment, strength of legacy brands, rapid ramp-up of new brands, effectiveness of advertising and promotional activity, and global distribution footprint as factors driving the firm’s 11% growth in second quarter sales to $342m. “Our three largest markets, North America, Western Europe and Asia/Pacific, grew sales by 5%, 11% and 5%, respectively,” while Central and South America sales grew at an “exceptional” 25%, reflecting a strong contribution from Lacoste fragrances, he notes in a 7 August earnings release.

The New York firm will be rolling out number of fragrance variations in the US in the back half of...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

SpotifyApple PodcastsWebsite

More from Earnings

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By Nabil

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.

Coty‘s Consumer Beauty Unit Will ‘Function Like A Startup’ To Launch More Products Quickly – Nabi

 
• By Eileen Francis

CEO Sue Nabi says Coty has created a “multi-functional, stand-alone organization” within its Consumer Beauty business to drive rapid-fire innovation. In a 20 August presentation, Nabi said the firm’s innovation pipeline undergirds its fiscal 2025 outlook of 6%-8% growth.

More from Business

HI-Beauty (Free-2): How the Future of Medicine Will Revolve Around Our Gut

 
• By Nabil

The gut’s microbiome will shape future medical advances, offering personalized therapies and prevention strategies for a wide range of diseases.

ADHD Medications and Cardiovascular Effects: New Data Revealed. (A Comprehensive Evaluation of Emerging Clinical and Epidemiological Evidence on the Cardiovascular Effects Associated with Commonly Prescribed Medications for Attention Deficit Hyperactivity Disorder)

 
• By Nabil

A look at new research on the cardiovascular effects of ADHD medications and what it means for clinical care. This article explores the latest clinical and epidemiological research on the cardiovascular effects of medications commonly prescribed for ADHD, examining potential heart-related risks, underlying mechanisms, and their implications for patient safety, clinical decision-making, and long-term treatment strategies across diverse age groups and risk profiles.